Print
|
Close
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Active:
Yes
Cancer Type:
Multiple Myeloma
NCT ID:
NCT07518186
Trial Phases:
Phase III
Protocol IDs:
79635322MMY3002 (primary)
NCI-2026-03376
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Janssen Research & Development, LLC
NCI Full Details:
http://clinicaltrials.gov/show/NCT07518186
Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with
teclistamab.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.